These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21037467)

  • 21. Checkpoint immunotherapy in head and neck cancers.
    Zolkind P; Uppaluri R
    Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Immunotherapy in Head and Neck Cancer.
    Ling DC; Bakkenist CJ; Ferris RL; Clump DA
    Semin Radiat Oncol; 2018 Jan; 28(1):12-16. PubMed ID: 29173750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.
    Cho J; Johnson DE; Grandis JR
    Semin Radiat Oncol; 2018 Jan; 28(1):2-11. PubMed ID: 29173752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospects for future studies in head and neck cancer.
    van Dongen GA; Snow GB
    Eur J Surg Oncol; 1997 Dec; 23(6):486-91. PubMed ID: 9484916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.
    Freiser ME; Serafini P; Weed DT
    Immunol Res; 2013 Dec; 57(1-3):52-69. PubMed ID: 24218361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?
    Ferris RL
    ORL J Otorhinolaryngol Relat Spec; 2004; 66(6):332-40. PubMed ID: 15668533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Moskovitz JM; Ferris RL
    J Dent Res; 2018 Jun; 97(6):622-626. PubMed ID: 29489423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
    Moy JD; Moskovitz JM; Ferris RL
    Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA-based immunotherapy for HPV-associated head and neck cancer.
    Aggarwal C
    Immunotherapy; 2016 Oct; 8(10):1187-92. PubMed ID: 27605067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Head and neck cancer immunotherapy: clinical evaluation.
    Leibowitz MS; Nayak JV; Ferris RL
    Curr Oncol Rep; 2008 Mar; 10(2):162-9. PubMed ID: 18377830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
    Laban S; Doescher J; Schuler PJ; Bullinger L; Brunner C; Veit JA; Hoffmann TK
    HNO; 2015 Sep; 63(9):612-9. PubMed ID: 26319429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
    Bowles DW; McDermott JD; Jimeno A
    Future Oncol; 2014 May; 10(6):1065-80. PubMed ID: 24941990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapeutic Approaches to Head and Neck Cancer.
    Nasser H; St John M
    Crit Rev Oncog; 2018; 23(3-4):161-171. PubMed ID: 30311572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.
    Outh-Gauer S; Alt M; Le Tourneau C; Augustin J; Broudin C; Gasne C; Denize T; Mirghani H; Fabre E; Ménard M; Scotte F; Tartour E; Badoual C
    Cancer Treat Rev; 2018 Apr; 65():54-64. PubMed ID: 29547766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 as an immunotherapeutic target in head and neck cancer.
    Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
    Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mTOR co-targeting strategies for head and neck cancer therapy.
    Wang Z; Valera JC; Zhao X; Chen Q; Gutkind JS
    Cancer Metastasis Rev; 2017 Sep; 36(3):491-502. PubMed ID: 28822012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunopharmacology of head and neck cancer: an update.
    Hadden JW
    Int J Immunopharmacol; 1997; 19(11-12):629-44. PubMed ID: 9669203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Covalent linking of proteins and cytokines to suture: enhancing the immune response of head and neck cancer patients.
    Shibuya TY; Kim S; Nguyen K; Parikh P; Wadhwa A; Brockardt C; Do J
    Laryngoscope; 2003 Nov; 113(11):1870-84. PubMed ID: 14603040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunotherapy for head and neck squamous cell carcinoma].
    Bron L; Romero P
    Rev Med Suisse; 2006 Oct; 2(81):2216-9. PubMed ID: 17076151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.